research Tyrosine Kinase Inhibitors: A Review on Pharmacology, Metabolism, and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
Search
for
Did you mean Tyrosine Kinase Inhibitors?
Sort by
Research
30 / 1000+ results
research Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
research Adverse Cutaneous Reactions to the New Second-Generation Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib) in Chronic Myeloid Leukemia
Many patients on new leukemia drugs had mild to moderate skin reactions.
research A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.
research Tyrosine Kinase Inhibitors in Dermatology: A Systematic Review
Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
research Keratosis Pilaris-Like Eruption During Chronic Myeloid Leukemia Treatment With Tyrosine Kinase Inhibitors: A Literature Review And Case Report On Imatinib
Some leukemia treatments can cause skin reactions similar to keratosis pilaris.
research Tyrosine Kinase Inhibitors Against Cancer: Their Safety in 216 Moroccan Patients
Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
research Taiwanese Dermatological Association Consensus for the Prevention and Management of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Related Skin Toxicities
The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.
research Acneiform Eruptions Caused by an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor ZD1839
ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
research Comparison of Pemetrexed and Docetaxel as Salvage Chemotherapy for the Treatment of Non-Small-Cell Lung Cancer After the Failure of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.
research Cerebral Ischemia Related to Isotretinoin; Venlafaxine-Induced Alopecia; Cognitive Dysfunction with Tolterodine; Retinal Artery Occlusion After Injection of Long-Acting Risperidone; Olanzapine-Induced Chylomicronemia Presenting as Pancreatitis; Metabolic Effects of the Atypical Antipsychotics – An Editorial; Another Drug-Induced Pancreatitis – This One Caused by a Tyrosine Kinase Inhibitor; Suicide Attempts Related to Antidepressant Medications
The conclusion is that healthcare professionals should report adverse drug reactions to improve medication safety and patient care.
research Cutaneous and Mucosal Side Effects of New Anticancer Drugs: EGF-R Inhibitors, Tyrosine Kinase Inhibitors, and Mitotic Spindle Stabilizers
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
research Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
research Epidermal Growth Factor Receptor Mutant T790M-L858R-V948R Inhibitor from Calophyllum Inophyllum L. Leaf as Potential Non-Small Cell Lung Cancer Drugs
A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.
research Activity of Sorafenib Against Desmoid Tumor/Deep Fibromatosis
Sorafenib is effective in treating Desmoid Tumor/Deep Fibromatosis.
research The PDGF/PDGFR Pathway as a Drug Target
The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
research Cutaneous Reactions to Chemotherapeutic Drugs and Targeted Therapy for Cancer
Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
research Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
A woman's hair turned white after taking a cancer drug called dasatinib.
research Hair Graying and Loss Induced by Imatinib Mesylate
A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.
research An Overview of Management of Drug-Induced Hair and Nail Disorders
Cooling the scalp may prevent hair loss from chemotherapy, hair often grows back after treatment, and nail issues usually improve after stopping the drug.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Erosive Pustular Dermatosis of the Scalp Induced by Gefitinib: Case and Review of the Literature
An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
research Nilotinib-Induced Generalized Keratosis Pilaris: Report of a Rare Case
Nilotinib can cause generalized keratosis pilaris.
research Unusual Progression of Renal Cell Carcinoma with Carcinomatosis Peritoneii and Krukenberg Tumor and Alopecia with Sunitinib Therapy in a Young Female
A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
research Hair Growth After Gefitinib Treatment
A man's bald spot grew hair after starting cancer treatment with gefitinib.
research Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
Gray hair can potentially be reversed, leading to new treatments.
research Severe Scarring Alopecia Associated with Combinational Use of Ficlatuzumab and Gefitinib: A Clinical and Immunohistochemistry Study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research Are All Adverse Effects Undesirable? A Case of Chemotherapy-Induced Adverse Effect - An Exception!
Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
research Dermal Fibroblasts Enhance Growth Factors Production by Androgens and Modulate Keratinocyte Proliferation and Differentiation
Androgens increase growth factors in skin cells, which may lead to acne.
research Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-Small Cell Lung Cancer
A cancer patient's eyelashes grew excessively without other common side effects after taking the cancer drug erlotinib.